Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Medivir AB ( (SE:MVIR) ) is now available.
Medivir AB’s interim report highlights the potential of its drug candidate, fostrox, combined with Lenvima, to become the first approved treatment for second-line liver cancer. The company is preparing for a pivotal phase 2b study, FOcuS-2, in collaboration with Eisai, aiming for breakthrough designation and accelerated market approval. Recent patent approvals in Europe, Japan, and Australia strengthen Medivir’s IP protection, providing market exclusivity until 2041. The company is also exploring strategic alternatives to support the study’s development, emphasizing the significant market opportunity for fostrox + Lenvima.
The most recent analyst rating on (SE:MVIR) stock is a Buy with a SEK54.00 price target. To see the full list of analyst forecasts on Medivir AB stock, see the SE:MVIR Stock Forecast page.
More about Medivir AB
Medivir AB is a pharmaceutical company focused on developing innovative cancer drugs, particularly for areas with high unmet medical needs. The company specializes in drug candidates targeting liver cancer, aiming to provide significant improvements for patients. Medivir collaborates with partners for drug development and is listed on Nasdaq Stockholm’s Small Cap list.
Average Trading Volume: 192,263
Technical Sentiment Signal: Sell
Current Market Cap: SEK218.5M
Find detailed analytics on MVIR stock on TipRanks’ Stock Analysis page.